Sandbox spb2013: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 75: | Line 75: | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''5.''' We suggest that [[FFP]] may be used if no other [[fibrinogen]] source is available.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''5.''' We suggest that [[FFP]] may be used if no other [[fibrinogen]] source is available.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''6.''' We suggest against the routine use of [[ | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''6.''' We suggest against the routine use of [[desmopressin]] in the absence of [[hemophilia A]] or mild [[von Willebrand disease]].''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''7.''' We suggest that perioperative [[antifibrinolytic therapy]] should be used to reduce [[blood loss]] and [[transfusion]] requirements in cardiac and non-cardiac pediatric [[surgery]].''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''7.''' We suggest that perioperative [[fibrinolytic|antifibrinolytic therapy]] should be used to reduce [[blood loss]] and [[transfusion]] requirements in cardiac and non-cardiac pediatric [[surgery]].''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | ||
|} | |||
Revision as of 15:17, 21 April 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
2013 ESA Guidelines for the Management of Severe Perioperative Bleeding (DO NOT EDIT)[1]
Class 1 |
"1. XXXXX. (Level of Evidence: A)" |
Class 1 |
"1. XXXXX. (Level of Evidence: A)" |
Class 2 |
"1. XXXXX.(Level of Evidence: A)" |
2013 ESA Guidelines for the Management of Severe Perioperative Bleeding (DO NOT EDIT)[1]
Acute Upper Gastrointestinal Bleeding
Class 1 |
"1. We recommend that acute variceal bleeding should be managed by a multidisciplinary team. A specific multimodal protocol for upper gastrointestinal hemorrhage should be available. (Level of Evidence: C)" |
"2. We recommend that early treatment involves immediate use of vasopressors (somatostatin or terlipressin) to reduce bleeding and early interventional endoscopy. Antibiotics must be started on admission. (Level of Evidence: A)" |
"3. rFVIIa should be used only as rescue therapy; we recommend against its routine use. (Level of Evidence: C)" |
Coagulopathy and Renal Disease
Class 2 |
"1. We suggest that conjugated estrogen therapy should be used in uremia.(Level of Evidence: C)" |
"2. We suggest that desmopressin should be considered for reducing bleeding during surgery and for managing acute bleeding in uremic patients.(Level of Evidence: C)" |
Pediatric Surgery
Class 1 |
"1. We recommend against the use of rFVIIa in children. (Level of Evidence: C)" |
Class 2 |
"1. We suggest the use of perioperative coagulation analysis using viscoelastic point-of-care monitoring (ROTEM/TEG) for timely detection of coagulation defects including dilutional coagulopathy and hyperfibrinolysis.(Level of Evidence: C)" |
"2. We suggest that a critical hemoglobin threshold of 8 g/dl for RBC transfusion may be safe in severe pediatric perioperative bleeding.(Level of Evidence: C)" |
"3. We suggest that transfusion of platelet concentrates may be considered if platelet count is <50,000–100,000/µl.(Level of Evidence: C)" |
"4. We suggest that fibrinogen concentrate (30–50 mg/kg) or cryoprecipitate (5 ml/kg) may be used to increase plasma fibrinogen concentrations above trigger values of 1.5–2.0 g/l or FIBTEM MCF > 7 mm in bleeding children.(Level of Evidence: C)" |
"5. We suggest that FFP may be used if no other fibrinogen source is available.(Level of Evidence: C)" |
"6. We suggest against the routine use of desmopressin in the absence of hemophilia A or mild von Willebrand disease.(Level of Evidence: C)" |
"7. We suggest that perioperative antifibrinolytic therapy should be used to reduce blood loss and transfusion requirements in cardiac and non-cardiac pediatric surgery.(Level of Evidence: A)" |
Sources
- 2013 ESA Guidelines for the Management of Severe Perioperative Bleeding[1]
References
- ↑ 1.0 1.1 1.2 Kozek-Langenecker, SA.; Afshari, A.; Albaladejo, P.; Santullano, CA.; De Robertis, E.; Filipescu, DC.; Fries, D.; Görlinger, K.; Haas, T. (2013). "Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology". Eur J Anaesthesiol. 30 (6): 270–382. doi:10.1097/EJA.0b013e32835f4d5b. PMID 23656742. Unknown parameter
|month=
ignored (help)